Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi, William Vainchenker
Journal of Clinical Oncology (2011) Vol. 29, Iss. 5, pp. 573-582
Closed Access | Times Cited: 318

Showing 1-25 of 318 citing articles:

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, et al.
Blood (2014) Vol. 124, Iss. 16, pp. 2507-2513
Open Access | Times Cited: 669
Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui, Guido Finazzi, Alessandra Carobbio, et al.
Blood (2012) Vol. 120, Iss. 26, pp. 5128-5133
Open Access | Times Cited: 543
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker, François Delhommeau, Stefan N. Constantinescu, et al.
Blood (2011) Vol. 118, Iss. 7, pp. 1723-1735
Open Access | Times Cited: 394
Myeloproliferative neoplasms and thrombosis
Tiziano Barbui, Guido Finazzi, Anna Falanga
Blood (2013) Vol. 122, Iss. 13, pp. 2176-2184
Open Access | Times Cited: 374
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi, Francisco Cervantes, Ruben A. Mesa, et al.
Blood (2013) Vol. 122, Iss. 8, pp. 1395-1398
Open Access | Times Cited: 339
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, et al.
Haematologica (2015) Vol. 100, Iss. 4, pp. 479-488
Open Access | Times Cited: 322
ATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation
Marit Westerterp, Andrea E. Bochem, Laurent Yvan‐Charvet, et al.
Circulation Research (2014) Vol. 114, Iss. 1, pp. 157-170
Open Access | Times Cited: 230
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 32, pp. 4993-5004
Open Access | Times Cited: 56
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Silvia Pascale, Giovanna Petrucci, Alfredo Dragani, et al.
Blood (2012) Vol. 119, Iss. 15, pp. 3595-3603
Open Access | Times Cited: 207
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz, Sigurður Y. Kristinsson, Therése Andersson, et al.
Journal of Clinical Oncology (2012) Vol. 30, Iss. 24, pp. 2995-3001
Open Access | Times Cited: 204
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Andrew Murphy, Nora Bijl, Laurent Yvan‐Charvet, et al.
Nature Medicine (2013) Vol. 19, Iss. 5, pp. 586-594
Open Access | Times Cited: 181
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Ayalew Tefferi
Blood (2012) Vol. 119, Iss. 12, pp. 2721-2730
Open Access | Times Cited: 169
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
Ayalew Tefferi, Thitina Jimma, Nanna Sulai, et al.
Leukemia (2011) Vol. 26, Iss. 3, pp. 475-480
Open Access | Times Cited: 160
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Damiano Rondelli, Judith D. Goldberg, Luis Isola, et al.
Blood (2014) Vol. 124, Iss. 7, pp. 1183-1191
Open Access | Times Cited: 145
The role of cytokines in the initiation and progression of myelofibrosis
Hans Carl Hasselbalch
Cytokine & Growth Factor Reviews (2013) Vol. 24, Iss. 2, pp. 133-145
Closed Access | Times Cited: 143
Juvenile myelomonocytic leukaemia and Noonan syndrome
Marion Strullu, Aurélie Caye, Julie Lachenaud, et al.
Journal of Medical Genetics (2014) Vol. 51, Iss. 10, pp. 689-697
Open Access | Times Cited: 129
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
Shahper N. Khan, A. Jankowska, Reda Z. Mahfouz, et al.
Leukemia (2013) Vol. 27, Iss. 6, pp. 1301-1309
Closed Access | Times Cited: 124
The adaptor Lnk (SH2B3): An emerging regulator in vascular cells and a link between immune and inflammatory signaling
Julie Devallière, Béatrice Charreau
Biochemical Pharmacology (2011) Vol. 82, Iss. 10, pp. 1391-1402
Closed Access | Times Cited: 123
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
Ting Zhou, Sandrine Georgeon, Roger Moser, et al.
Leukemia (2013) Vol. 28, Iss. 2, pp. 404-407
Open Access | Times Cited: 113
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
Hajnalka Andrikovics, Tünde Krähling, Katalin Balassa, et al.
Haematologica (2014) Vol. 99, Iss. 7, pp. 1184-1190
Open Access | Times Cited: 99
Leukemic Transformation in Myeloproliferative Neoplasms
Meera Yogarajah, Ayalew Tefferi
Mayo Clinic Proceedings (2017) Vol. 92, Iss. 7, pp. 1118-1128
Open Access | Times Cited: 88
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
Richard T. Silver, Jean‐Jacques Kiladjian, Hans Carl Hasselbalch
Expert Review of Hematology (2013) Vol. 6, Iss. 1, pp. 49-58
Closed Access | Times Cited: 101
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases
Angela V. Toms, Anagha Deshpande, Randall McNally, et al.
Nature Structural & Molecular Biology (2013) Vol. 20, Iss. 10, pp. 1221-1223
Open Access | Times Cited: 96
RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation
Paola Ballerini, Stéphanie Struski, Charlotte Cresson, et al.
Leukemia (2012) Vol. 26, Iss. 11, pp. 2384-2389
Closed Access | Times Cited: 95
Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Warren Fiskus, Srđan Verstovšek, Taghi Manshouri, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 23, pp. 7347-7358
Open Access | Times Cited: 95
Page 1 - Next Page

Scroll to top